PharmaPoint: Multiple Sclerosis - Current and Future Players

NEW YORK, April 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Multiple Sclerosis - Current and Future Players
http://www.reportlinker.com/p01158410/PharmaPoint-Multiple-Sclerosis---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Multiple Sclerosis - Current and Future Players

Summary

GlobalData has released its pharma report, "PharmaPoint: Multiple Sclerosis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Multiple Sclerosis Market. The report identifies and analyses the key companies shaping and driving the global Multiple Sclerosis market. The report provides insight into the competitive Multiple Sclerosis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

- Investigation of current and future market competition for Multiple Sclerosis
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of the Multiple Sclerosis sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving the Multiple Sclerosis Market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What's the next big thing in the global Multiple Sclerosis market landscape? Identify, understand and capitalize

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Market Outlook 11
3.1 Global Markets 11
3.1.1 Forecast 11
3.1.2 Drivers and Barriers – Global Issues 13
4 Current and Future Players 17
4.1 Overview 17
4.2 Trends in Corporate Strategy 19
4.3 Company Profiles 21
4.3.1 Biogen Idec 21
4.3.2 Teva Pharmaceutical Industries 24
4.3.3 Merck Serono (EMD Serono) 27
4.3.4 Sanofi 30
4.3.5 Bayer HealthCare Pharmaceuticals 33
4.3.6 Novartis International 35
4.3.7 Hoffmann-La Roche 38
4.3.8 GlaxoSmithKline 40
5 Appendix 42
5.1 Bibliography 42
5.2 Abbreviations 42
5.3 Methodology 43
5.4 Forecasting Methodology 43
5.4.1 Diagnosed MS patients 43
5.4.2 Percent Drug-Treated Patients 44
5.4.3 Drugs Included in Each Therapeutic Class 44
5.4.4 Launch and Patent Expiry Dates 45
5.4.5 General Pricing Assumptions 46
5.4.6 Individual Drug Assumptions 47
5.4.7 Generic Erosion 50
5.4.8 Pricing of Pipeline agents 51
5.5 Physicians and Specialists Included in This Report 52
5.6 Primary Research – Prescriber Survey 53
5.7 About the Authors 53
5.7.1 Analysts 53
5.7.2 Global Head of Healthcare 54
5.8 About GlobalData 55
5.9 Contact Us 55
5.10 Disclaimer 55

List of Tables

Table 1: Global Sales Forecasts ($m) for Multiple Sclerosis, 2012–2022 12
Table 2: Global Multiple Sclerosis Market – Drivers and Barriers, 2012 13
Table 3: Key Companies in the Multiple Sclerosis Market, 2012 18
Table 4: Biogen's Multiple Sclerosis Portfolio Assessment, 2012 22
Table 5: Biogen SWOT Analysis, 2012 23
Table 6: Teva's Multiple Sclerosis Portfolio Assessment, 2012 25
Table 7: Teva SWOT Analysis, 2012 26
Table 8: Merck's Multiple Sclerosis Portfolio Assessment, 2012 28
Table 9: Merck SWOT Analysis, 2012 29
Table 10: Sanofi's Multiple Sclerosis Portfolio Assessment, 2012 31
Table 11: Sanofi SWOT Analysis, 2012 32
Table 12: Bayer's Multiple Sclerosis Portfolio Assessment, 2012 34
Table 13: Bayer SWOT Analysis, 2012 34
Table 14: Novartis' Multiple Sclerosis Portfolio Assessment, 2012 36
Table 15: Novartis SWOT Analysis, 2012 37
Table 16: Roche's Multiple Sclerosis Portfolio Assessment, 2012 39
Table 17: Roche SWOT Analysis, 2012 39
Table 18: GlaxoSmithKiline's Multiple Sclerosis Portfolio Assessment, 2012 41
Table 19: GlaxoSmithKline SWOT Analysis, 2012 41
Table 20: Key Launch Dates 45
Table 21: Key Patent Expiries 45
Table 22: Physicians Surveyed, By Country 53

List of Figures

Figure 1: Global Market Sales for Multiple Sclerosis by Region, 2012–2022 13
Figure 2: Company Portfolio Gap Analysis in Multiple Sclerosis, 2012–2022 20

Companies Mentioned

Biogen Idec
Teva Pharmaceutical Industries
Merck Serono (EMD Serono)
Sanofi
Bayer HealthCare Pharmaceuticals
Novartis International
Hoffmann-La Roche
GlaxoSmithKline

To order this report:
Pathology Industry: PharmaPoint: Multiple Sclerosis - Current and Future Players

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker